Maheswari Senthil1, Preeti Chaudhary2, David D Smith3, Patrick E Ventura3, Paul H Frankel3, Vinod Pullarkat2, Vijay Trisal4. 1. Department of Surgery, City of Hope Medical Center, Duarte, California 91010. 2. Division of Hematology, University of Southern California Keck School of Medicine, Los Angeles, California 90033. 3. Division of Biostatistics, City of Hope Medical Center, Duarte, California 91010. 4. Department of Surgery, City of Hope Medical Center, Duarte, California 91010. Electronic address: VTrisal@coh.org.
Abstract
INTRODUCTION: Hypercoagulability due to high coagulation factor levels resulting from host inflammatory response to cancer contributes to an increased risk of venous thromboembolism (VTE) in cancer patients. Central venous catheters (CVCs) further heighten this risk. Activated partial thromboplastin time (aPTT) can be used to broadly screen for elevated levels of relevant coagulation factors. Our objective was to determine if a shortened aPTT ratio (coagulation time of test- to- reference plasma) was a predictor of CVC-associated VTE in cancer patients. MATERIALS AND METHODS: We performed a retrospective case-control study on cancer patients undergoing tunneled CVC insertion at our center from 1999 to 2006 and identified 40 patients who had CVC-associated VTE. VTE was confirmed with color duplex ultrasonography or computed tomography scan. For each case, we obtained 5 controls that had the same cancer diagnosis and were matched on the following factors: age, chemotherapy, hormone therapy (if applicable), tobacco use, TNM staging and year of diagnosis. All patients had aPTT testing within 30 days prior to surgery. We compared aPTT and aPTT ratio between cases and controls using Wilcoxon two sample test. RESULTS: aPTT ratio was significantly shorter in patients with CVC-related VTE as compared to controls [0.86 (95% confidence interval (CI) 0.78, 0.94) vs. 0.98 (0.94, 1.01), p=0.0003]. Mean aPTT was also significantly shorter. [25.6 seconds (95% CI 23.2, 27.9) vs. 28.1 (26.9, 29.3), p=0.001] aPTT ratios of the controls tended to spread across larger aPTT ratio values whereas those of cases tended to clustered around the mean. CONCLUSIONS: Cancer patients undergoing catheter placement who develop CVC-associated VTE have a shorter aPTT and aPTT ratio than those who do not develop VTE. aPTT, a simple and inexpensive test might be useful as a predictor of CVC-associated VTE risk in cancer patients.
INTRODUCTION: Hypercoagulability due to high coagulation factor levels resulting from host inflammatory response to cancer contributes to an increased risk of venous thromboembolism (VTE) in cancerpatients. Central venous catheters (CVCs) further heighten this risk. Activated partial thromboplastin time (aPTT) can be used to broadly screen for elevated levels of relevant coagulation factors. Our objective was to determine if a shortened aPTT ratio (coagulation time of test- to- reference plasma) was a predictor of CVC-associated VTE in cancerpatients. MATERIALS AND METHODS: We performed a retrospective case-control study on cancerpatients undergoing tunneled CVC insertion at our center from 1999 to 2006 and identified 40 patients who had CVC-associated VTE. VTE was confirmed with color duplex ultrasonography or computed tomography scan. For each case, we obtained 5 controls that had the same cancer diagnosis and were matched on the following factors: age, chemotherapy, hormone therapy (if applicable), tobacco use, TNM staging and year of diagnosis. All patients had aPTT testing within 30 days prior to surgery. We compared aPTT and aPTT ratio between cases and controls using Wilcoxon two sample test. RESULTS: aPTT ratio was significantly shorter in patients with CVC-related VTE as compared to controls [0.86 (95% confidence interval (CI) 0.78, 0.94) vs. 0.98 (0.94, 1.01), p=0.0003]. Mean aPTT was also significantly shorter. [25.6 seconds (95% CI 23.2, 27.9) vs. 28.1 (26.9, 29.3), p=0.001] aPTT ratios of the controls tended to spread across larger aPTT ratio values whereas those of cases tended to clustered around the mean. CONCLUSIONS:Cancerpatients undergoing catheter placement who develop CVC-associated VTE have a shorter aPTT and aPTT ratio than those who do not develop VTE. aPTT, a simple and inexpensive test might be useful as a predictor of CVC-associated VTE risk in cancerpatients.
Authors: Daren M Beam; Evandro M Neto-Neves; William B Stubblefield; Nathan J Alves; Johnathan D Tune; Jeffrey A Kline Journal: Comp Med Date: 2015-02 Impact factor: 0.982
Authors: Lin Zhang; Juan Ye; Qiuyun Luo; Miaohuan Kuang; Minjie Mao; Shuqin Dai; Xueping Wang Journal: Cancer Manag Res Date: 2020-07-03 Impact factor: 3.989
Authors: Zhijian He; Xiaomeng Wan; Anita Schulz; Herdis Bludau; Marina A Dobrovolskaia; Stephan T Stern; Stephanie A Montgomery; Hong Yuan; Zibo Li; Daria Alakhova; Marina Sokolsky; David B Darr; Charles M Perou; Rainer Jordan; Robert Luxenhofer; Alexander V Kabanov Journal: Biomaterials Date: 2016-06-04 Impact factor: 12.479
Authors: Yang Song; Shuang Liu; Ting Lou; Yuxiu Ma; Na Wang; Qinge Yong; Lin Cong; Zheng Xiao; Gao Liu Journal: J Int Med Res Date: 2019-01-11 Impact factor: 1.671